Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact (Q57579477)
Jump to navigation
Jump to search
scientific article published on 14 May 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact |
scientific article published on 14 May 2014 |
Statements
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact (English)
J M Nabholtz
M A Mouret-Reynier
M M Dauplat
B Weber
A M Forest
T Petit
S Guiu
I Van Praagh
C Jouannaud
P Dubray-Longeras
K E Benmammar
S Kullab
M R K Bahadoor
N Radosevic-Robin
F Kwiatkowski
A Desrichard
N Uhrhammer
N Chalabi
P Chollet
F Penault-Llorca
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference